AUTOMATIC SUBDERMAL INJECTOR SYSTEM, INC Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2016
NCT02074150
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

AUTOMATIC SUBDERMAL INJECTOR SYSTEM INC | AUTOMATIC SUBDERMAL INJECTOR SYSTEM,INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Immunologic Deficiency Syndromes (Phase 2)

Migraine Disorders (Phase 2)

Muscle Hypertonia (Phase 2)

Muscle Spasticity (Phase 2)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 4